Amgen Inc (AMGN)
270.05
+0.67
(+0.25%)
USD |
NASDAQ |
Apr 26, 16:00
270.05
0.00 (0.00%)
After-Hours: 20:00
Amgen SG&A Expense (Quarterly): 2.274B for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 2.274B |
September 30, 2023 | 1.353B |
June 30, 2023 | 1.294B |
March 31, 2023 | 1.258B |
December 31, 2022 | 1.572B |
September 30, 2022 | 1.287B |
June 30, 2022 | 1.327B |
March 31, 2022 | 1.228B |
December 31, 2021 | 1.425B |
September 30, 2021 | 1.305B |
June 30, 2021 | 1.384B |
March 31, 2021 | 1.254B |
December 31, 2020 | 1.773B |
September 30, 2020 | 1.346B |
June 30, 2020 | 1.295B |
March 31, 2020 | 1.316B |
December 31, 2019 | 1.513B |
September 30, 2019 | 1.223B |
June 30, 2019 | 1.26B |
March 31, 2019 | 1.154B |
December 31, 2018 | 1.559B |
September 30, 2018 | 1.293B |
June 30, 2018 | 1.353B |
March 31, 2018 | 1.127B |
December 31, 2017 | 1.427B |
Date | Value |
---|---|
September 30, 2017 | 1.17B |
June 30, 2017 | 1.209B |
March 31, 2017 | 1.064B |
December 31, 2016 | 1.323B |
September 30, 2016 | 1.244B |
June 30, 2016 | 1.292B |
March 31, 2016 | 1.203B |
December 31, 2015 | 1.416B |
September 30, 2015 | 1.244B |
June 30, 2015 | 1.16B |
March 31, 2015 | 1.026B |
December 31, 2014 | 1.327B |
September 30, 2014 | 1.213B |
June 30, 2014 | 1.136B |
March 31, 2014 | 1.023B |
December 31, 2013 | 1.521B |
September 30, 2013 | 1.249B |
June 30, 2013 | 1.256B |
March 31, 2013 | 1.158B |
December 31, 2012 | 1.373B |
September 30, 2012 | 1.131B |
June 30, 2012 | 1.231B |
March 31, 2012 | 1.079B |
December 31, 2011 | 1.221B |
September 30, 2011 | 1.125B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.223B
Minimum
Sep 2019
2.274B
Maximum
Dec 2023
1.405B
Average
1.316B
Median
Mar 2020
SG&A Expense (Quarterly) Benchmarks
Gilead Sciences Inc | 1.608B |
Johnson & Johnson | 5.257B |
Eli Lilly and Co | 1.463B |
Merck & Co Inc | 2.804B |
Vertex Pharmaceuticals Inc | 369.10M |